Clinical trial registry record

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 21, 2017.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00593450
Last registry update
August 21, 2017
Status
Completed
Phase
Phase 3
Sponsor
University of Pennsylvania
Enrollment
1208
Countries
United States
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
1208
Population
ALL · 50 Years
Duration
2008-02-01 to 2015-04-01
Intervention
ranibizumab; bevacizumab
Comparator
1
Outcomes measured
Change From Baseline in Visual-acuity Score (Continuous) — Baseline and 1 Year; Change From Baseline Visual-acuity Score (Frequency) — Baseline and 1 Year; Visual-acuity Score and Snellen Equivalent (Frequency) — at 1 Year; Visual-acuity Score and Snellen Equivalent (Continuous) — at 1 Year; Number of Treatments — 1 Year; Average Cost of Drug/Patient — at 1 Year; Total Thickness at Fovea — at 1 Year; Total Thickness Change From Baseline at Fovea — Baseline and 1 Year; Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea — at 1 Year; Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea — Baseline and 1 Year; Fluid on Optical Coherence Tomography — at 1 Year; Dye Leakage on Angiogram — at 1 Year; Area of Lesion — at 1 Year; Area of Lesion Change From Baseline — Baseline and 1 Year; Change in Systolic Blood Pressure From Baseline — Baseline and 1 Year; Change in Diastolic Blood Pressure From Baseline — Baseline and 1 Year
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON